Pharma's Market
SPECIAL REPORT
MOST SHARED
- Marc Faber: 100% Chance of Global Recession
- Time for Flash Sales to Adapt or Die
- How to Trade on the Jobs Report
- Citigroup Lost $20 Million on Facebook IPO Trades
- Don’t Trust Buybacks
- Buy Broken Stocks, Not Broken Companies
- The Biggest Market Myth There Is?
- Facebook: The Song — Yes, We're Serious
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Buying the Right Sell-Off Stocks
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- Citigroup Lost $20 Million on Facebook IPO Trades
- Sticker Shock: What College Is Likely to Cost in 18 Years
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- Icahn Raises Stake in Chesapeake, Wants Board Seats
- Marc Faber: Chance of Global Recession Is Now 100%
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- What Happened to Stocks? Most Unloved in 50 Years
- Cool Jobs: From Gold Stacker to Bed Tester
- Many Greeks Moved Their Money Abroad Long Ago
RSS FEED
Biotech Bonanza At Industry Conference
Text Size 
Reporter
Today I will be attending and blogging from the 15th Annual Newsmakers in the Biotech Industry conference which is put on by BioCentury Publications and Thomson Reuters. Three dozen biotechs will be making presentations and then doing hour-long q and a's during breakout sessions.
Obviously I can't hit them all, but I will try to post bullet points and highlights here throughout the day from the handful I plan to sit in on. Among them the sessions I hope to make are Medivation (fresh off its big news yesterday about its Pfizer partnership), Orexigen, Arena Pharmaceuticals, Amylin Pharmaceuticals (its first presentation since announcing the additional patient deaths), Celgene and, yes, Dendreon.
Organizers are expecting more than 850 people to show up at the event taking place at a hotel in midtown Manhattan.
According to a press release, the presenting companies have added $18 billion in market cap so far this year as of the middle of last month. In the aggregate, their stocks are up 50 percent versus an 11 percent rise in the Nasdaq Biotech Index. Check back here for my dispatches.
Pfizer Finding Innovation At Medivation
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
